Kyunghee Choi, Ph.D.

Pathology and Immunology

Developmental, Regenerative and Stem Cell Biology Program
Immunology Program
Cancer Biology Program
Molecular Cell Biology Program

  • 314-362-8716

  • 314-362-9045

  • 314-747-0809

  • BJCIH 8th floor, room 8302


  • Cell fate, transcription factors, hematopoiesis, vascular, development, regeneration, stem cells, tumor angiogenesis, tumor immunity

  • Angioimmune interface in development, tissue regeneration, and cancer

Research Abstract:

Hematopoietic and endothelial development:
We study hematopoietic and endothelial cell development. We focus on the molecular mechanisms that control mesoderm commitment to the hematopoietic and endothelial cell lineages. Particularly, we investigate the interaction among VEGF, Flk1, and an ETS transcription factor ETV2, as these three factors play a deterministic role in the formation of hematopoietic and endothelial cells. We have expertise in hematopoietic, vascular, and stem cell biology and stem cell applications.

Hematopoiesis and angiogenesis in cancer:
We study hematopoiesis and angiogenesis in the context of cancer. Particularly, we investigate mechanisms that lead to hematopoietic stem and progenitor changes in the tumor. We also investigate mechanisms by which tumor angiogenesis affects tumor immunity. We hope to apply the knowledge obtained from these studies to ultimately modulate tumor immunity and tumor growth.

Selected Publications:

Kabir, A.U., Subramanian, M., Lee, D.H., Wang, X., Krchma, K. Wu, J., Naismith, T., Halabi, C.M., Kim, J.Y., Pulous, F., Petrich, B., Kim, S., Park, H-C., Hanson, P.I., Pan, H., Wickline, S.A., Fremont, D.H., Park, C., and Choi, K. 2021. Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity. Science Translational Medicine 13(583):eabb6731.
Full text:

Wu, J., Krchma, K., Lee, H.J., Prabhakar, S., Wang, X., Zhao, H., Xing, X., Seong, R.H., Fremont, D.H., Artyomov, M.N., Wang, T. and, Choi K. 2020. Requisite Chromatin Remodeling for Myeloid and Erythroid Lineage Differentiation from Erythromyeloid Progenitors. Cell Rep. 33(7):108395.

Zhao, H. and Choi, K. 2019.Single cell transcriptome dynamics from pluripotency to FLK1+ mesoderm. Development. 146(23). pii: dev182097. doi: 10.1242/dev.182097.

Kabir, A.U., Lee, T-J., Pan, H., Berry, J.C., Krchma, K., Wu, J., Liu, F., Kang, H-K., Hinman, K., Yang, L., Hamilton, S., Novack, D.V., Mecham, R.P., Wickline, S.A., Miller, M.J. and Choi, K. 2018. Requisite endothelial reactivation and effective siRNA nanoparticle targeting of Etv2/Er71 in tumor angiogenesis. JCI Insight. 3(8):e97349. doi:10.1172/jci.insight.97349.

Zhao, H., and Choi, K. 2017. A CRISPR screen identifies genes controlling Etv2 threshold expression in hemangiogenic fate commitment. Nature Communications. 8(1):541. doi: 10.1038/s41467-017-00667-5.

Xu, C., Lee, T., Sakurai, N., Krchma, K., Liu, F., Li, D., Wang, T. and Choi, K. 2017. ETV2/ER71 regulates hematopoietic regeneration through hematopoietic stem cell proliferation. J. Exp. Med. 214(6):1643-1653.

Last Updated: 11/12/2021 10:41:19 AM

Back To Top

Follow us: